Form 4: Oncocyte Corp Director Andrew Arno Reports Stock Option Grant

Director Andrew Arno reports the acquisition of stock options in Oncocyte Corp.

Summary

• Andrew Arno, a director of Oncocyte Corp, filed a Form 4 on July 3, 2024, reporting a transaction.
• On July 1, 2024, Arno acquired an option to purchase 30,000 shares of Oncocyte Corp common stock at an exercise price of $2.95.
• The options vest one year from the grant date, contingent upon continued service as a director until the vesting date or the next annual shareholder meeting.
• Following the transaction, Arno directly owns options for 30,000 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the sentiment is neutral. It reflects standard compensation practices.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of one year is typical, ensuring continued service and commitment from the director.
• The exercise price is a key factor, and its relationship to the current market price will determine the potential value of the options to the director.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.
• The dilution effect of potential future share issuance upon option exercise is minimal given the relatively small number of shares involved.

Key Dates